# First in Human Study in Healthy Volunteers of Antimicrobial Peptide PL-18 Vaginal Suppositories

> **NCT05340790** · PHASE1 · UNKNOWN · sponsor: **Protelight Pharmaceuticals Australia PTY LTD** · enrollment: 50 (estimated)

## Conditions studied

- Colpomycosis
- Bacterial Vaginosis
- Mixede Vaginitis

## Interventions

- **DRUG:** Dose 1 to 5 of Antimicrobial Peptide PL-18 Vaginal Suppositories
- **DRUG:** Placebo dose 1 to 5 of Antimicrobial Peptide PL-18 Vaginal Suppositories

## Key facts

- **NCT ID:** NCT05340790
- **Lead sponsor:** Protelight Pharmaceuticals Australia PTY LTD
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-08-01
- **Primary completion:** 2023-12-04
- **Final completion:** 2024-03-01
- **Target enrollment:** 50 (ESTIMATED)
- **Last updated:** 2023-12-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05340790

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05340790, "First in Human Study in Healthy Volunteers of Antimicrobial Peptide PL-18 Vaginal Suppositories". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05340790. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*